Here is What Hedge Funds Think About NanoViricides Inc (NNVC)

You probably know from experience that there is not as much information on small-cap companies as there is on large companies. Of course, this makes it really hard and difficult for individual investors to make proper and accurate analysis of certain small-cap companies. However, well-known and successful hedge fund investors like Carl Icahn and George Soros hold the necessary resources and abilities to conduct an extensive stock analysis on small-cap stocks, which enable them to make millions of dollars by identifying potential winners within the small-cap galaxy of stocks. This represents the main reason why Insider Monkey takes notice of the hedge fund activity in these overlooked stocks.

NanoViricides Inc (NYSEMKT:NNVC) shares haven’t seen a lot of action during the third quarter. Overall, hedge fund sentiment was unchanged. The stock was in 4 hedge funds’ portfolios at the end of September. At the end of this article we will also compare NNVC to other stocks including TearLab Corporation (NASDAQ:TEAR), Datawatch Corporation (NASDAQ:DWCH), and AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) to get a better sense of its popularity.

Keeping this in mind, we’re going to analyze the recent action encompassing NanoViricides Inc (NYSEMKT:NNVC).

Hedge fund activity in NanoViricides Inc (NYSEMKT:NNVC)

Of the funds tracked by Insider Monkey, Millennium Management, managed by Israel Englander, holds the most valuable position in NanoViricides Inc (NYSEMKT:NNVC). Millennium Management has a $0.2 million position in the stock, comprising less than 0.1% of its 13F portfolio. On Millennium Management’s heels is Renaissance Technologies, led by Jim Simons, holding a $0.1 million position; less than 0.1% of its 13F portfolio is allocated to the company. Remaining members of the smart money that hold long positions include D. E. Shaw’s D E Shaw, and Ken Griffin’s Citadel Investment Group.